DexCom Inc. (DXCM): Price and Financial Metrics


DexCom Inc. (DXCM): $112.00

-0.92 (-0.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DXCM POWR Grades

  • DXCM scores best on the Growth dimension, with a Growth rank ahead of 94% of US stocks.
  • The strongest trend for DXCM is in Stability, which has been heading up over the past 179 days.
  • DXCM ranks lowest in Momentum; there it ranks in the 1st percentile.

DXCM Stock Summary

  • With a market capitalization of $44,925,682,519, DEXCOM INC has a greater market value than 94.81% of US stocks.
  • With a price/earnings ratio of 195.33, DEXCOM INC P/E ratio is greater than that of about 97.88% of stocks in our set with positive earnings.
  • The volatility of DEXCOM INC's share price is greater than that of 97.8% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to DEXCOM INC, a group of peers worth examining would be FSLR, NBIX, CALX, MELI, and ESMT.
  • DXCM's SEC filings can be seen here. And to visit DEXCOM INC's official web site, go to www.dexcom.com.

DXCM Valuation Summary

  • In comparison to the median Healthcare stock, DXCM's EV/EBIT ratio is 2121.05% higher, now standing at 168.8.
  • DXCM's EV/EBIT ratio has moved up 189.2 over the prior 214 months.

Below are key valuation metrics over time for DXCM.

Stock Date P/S P/B P/E EV/EBIT
DXCM 2022-11-01 16.5 25.2 199.9 168.8
DXCM 2022-10-31 16.7 25.6 202.8 171.2
DXCM 2022-10-28 16.7 25.6 203.0 171.3
DXCM 2022-10-27 14.0 21.4 170.0 144.3
DXCM 2022-10-26 15.1 17.9 201.7 166.2
DXCM 2022-10-25 14.8 17.6 198.5 163.6

DXCM Growth Metrics

    Its 5 year revenue growth rate is now at 179.19%.
  • The 2 year cash and equivalents growth rate now stands at 22.48%.
  • The 4 year net income to common stockholders growth rate now stands at 325.46%.
Over the past 15 months, DXCM's revenue has gone up $622,900,000.

The table below shows DXCM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 2,792.8 642.8 230
2022-06-30 2,673.4 596.9 199.7
2022-03-31 2,572.3 485.7 211.7
2021-12-31 2,448.5 442.5 154.7
2021-09-30 2,319.2 508.7 529.3
2021-06-30 2,169.9 409 530.6

DXCM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • DXCM has a Quality Grade of B, ranking ahead of 87.89% of graded US stocks.
  • DXCM's asset turnover comes in at 0.517 -- ranking 89th of 186 Medical Equipment stocks.
  • VRAY, ZYXI, and SRTS are the stocks whose asset turnover ratios are most correlated with DXCM.

The table below shows DXCM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.517 0.693 0.081
2021-06-30 0.510 0.692 0.077
2021-03-31 0.506 0.675 0.070
2020-12-31 0.547 0.664 0.077
2020-09-30 0.597 0.654 0.089
2020-06-30 0.651 0.639 0.090

DXCM Price Target

For more insight on analysts targets of DXCM, see our DXCM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $530.60 Average Broker Recommendation 1.36 (Strong Buy)

DXCM Stock Price Chart Interactive Chart >

Price chart for DXCM

DXCM Price/Volume Stats

Current price $112.00 52-week high $152.62
Prev. close $112.92 52-week low $66.89
Day low $110.65 Volume 1,182,900
Day high $113.02 Avg. volume 3,209,266
50-day MA $101.39 Dividend yield N/A
200-day MA $95.07 Market Cap 43.26B

DexCom Inc. (DXCM) Company Bio


Dexcom was founded in 1999 by Scott Glenn, John Burd, Lauren Otsuki, Ellen Preston and Bret Megargel. In 2006, Dexcom received U.S. Food and Drug Administration (FDA) approval and launched the Dexcom STS Continuous Glucose Monitoring System, which is a three-day sensor that provides up to 288 glucose measurements for every 24 hours. Dexcom received approval of the second generation product, the Seven Continuous Glucose Monitoring System in May 2007. This device improved on accuracy and extended use from three to seven days. In 2008, Dexcom announced two consumer development agreements with Insulet Corporation and Animas Corporation as well as a development agreement with Edwards Lifesciences for a continuous glucose monitor in the intensive care unit hospital environment. (Source:Wikipedia)


DXCM Latest News Stream


Event/Time News Detail
Loading, please wait...

DXCM Latest Social Stream


Loading social stream, please wait...

View Full DXCM Social Stream

Latest DXCM News From Around the Web

Below are the latest news stories about DEXCOM INC that investors may wish to consider to help them evaluate DXCM as an investment opportunity.

Why The Market Rally Could Use A Holiday; Tesla Rebounds, 5 Stocks Near Buy Points

The S&P 500 still faces its 200-day line with key economic data looming. Tesla rebounded from bear market lows while five medical stocks are near buy points.

Yahoo | November 23, 2022

Dexcom Announces Upcoming Conference Presentation

SAN DIEGO, November 22, 2022--DexCom, Inc. (NASDAQ:DXCM) today announced that Matt Dolan, Executive Vice President, Strategy, Corporate Development and Dexcom Labs, will present an update on the company at the Piper Sandler 34th Annual Healthcare Conference on Wednesday, November 30, 2022 at 8:30am (EST).

Yahoo | November 22, 2022

3 Stocks to Buy for Long-Term Growth Upside

Investors might want to consider buying stocks after the strong first half of the fourth quarter. Today, we explore three stocks that are set to expand within three crucial growth industries.

Yahoo | November 18, 2022

Head-And-Shoulders Pattern Spots Short-Sale Entries, But Beware Of Potential Headaches

When it comes to selling short, there is one pattern that stands head and shoulders above the rest, in a manner of speaking.

Yahoo | November 18, 2022

2 Unstoppable Growth Stocks to Buy in 2022 and Beyond

While growth stocks aren't attracting the interest from investors that they were a few years ago, not all businesses that fall into this category of investments have dealt with the same headwinds as many former pandemic favorites. Today, we're going to take a look at two top healthcare stocks with growth-driven businesses that have a robust track record of rewarding investors. Intuitive Surgical (NASDAQ: ISRG) is a name known to many healthcare investors for its profitable and fast-growing surgical robotics business, which has led it to deliver a total return of about 345% to investors over the past decade.

Yahoo | November 16, 2022

Read More 'DXCM' Stories Here

DXCM Price Returns

1-mo -7.34%
3-mo 34.32%
6-mo 50.37%
1-year -24.32%
3-year 96.90%
5-year 674.95%
YTD -16.57%
2021 45.23%
2020 69.02%
2019 82.59%
2018 108.75%
2017 -3.87%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7532 seconds.